ClinicalTrials.gg
RecruitingNCT05943067CD45RADLIHaploUpdated Apr 27, 2025

CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT

A Phase 1/2 interventional study of CD45RA depleted donor lymphocyte infusion (DLI) in Hematologic Malignancy, sponsored by University Hospital Tuebingen. Recruiting at 2 sites in Germany. Open to participants aged 8 Weeks to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-27.

Sponsored by University Hospital Tuebingen · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
8 Weeks to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Hematologic Neoplasms with a site in Germany — 20 open to participants now, 28 under way, 3 of them phase 3. Hematologic Neoplasms · Germany.

Planned enrollment
33rd of 50
60 · median 91
Started
2023
with 3 others
Phase 1/2
11 of 65
1 open now
Primary completion
2028-01
later than 15 of 27 live
Registered
56th of 65
by date
Lead sponsor
3 of 65
University Hospital Tuebingen

Among the 65 studies in Hematologic Neoplasms with a site in Germany, this one is the 33rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 4 that started in 2023, is one of 11 in phase 1/2, reaches primary completion later than 15 of the 27 other live ones, and was the 56th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

20 of the 65 studies in Hematologic Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 8 Weeks to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Hematologic Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to examine safety and toxicity of CD45RA depleted donor lymphocyte infusion (DLI) after transplantation of TCRα/β/CD19 depleted peripheral blood stem cells.

Read the detailed description

Patients will undergo routine reduced intensity conditioning regimen and intravenous infusion of T-cell receptor alpha/beta (TCRα/β)/CD19 depleted peripheral blood stem cells (not content of clinical trial).

If no graft-versus-host disease (GVHD) occurs, patients receive the trial-related memory T cell donor lymphocyte infusion (DLI) on Day 30 after transplantation.

In a dose finding part (phase I) escalating doses will be applied in cohorts of three (three plus three design) patients with a maximum of 18 patients for three dose levels (dose level 1-3). A fourth lower dose level (dose level 0) is started, if >=2 out of 6 patients with dose level 1 develop aGVHD III/IV. The maximum tolerated dose (MTD) will be used for the confirmatory part (phase II) of the study.

03

Conditions studied

  • Hematologic Malignancy
04

Who can participate

Ages eligible
8 Weeks to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult and pediatric patients with hematological in complete remission (CR), partial remission (PR) or with stable disease

  • Acute myeloid leukemia (AML):

    • Patients with high-risk AML in first complete remission (CR1)
    • Patients with or primary therapy-refractory AML
  • Acute lymphoid leukemia (ALL):

    • Patients with high-risk ALL in CR1
    • Patients with relapsed or primary refractory ALL
  • Hodgkin's disease: Patients with relapsed or primary refractory Hodgkin's disease
  • Non-Hodgkin's lymphoma: Patients with relapsed or primary refractory Non- Hodgkin's lymphoma
  • Myelodysplastic Syndrome (MDS)/ Myeloproliferative Syndrome (MPS):

    °Patients with refractory MDS/MPS

  • Multiple myeloma (MM): Patients with relapsed or refractory multiple myeloma

Exclusion criteria

Exclusion Criteria:

  • Age >65 years or \<8 weeks
  • Patients with progressive disease prior hematopoietic cell transplantation (HCT)
  • \<3 months after preceding HCT
  • Treatment with T-cell or Interleukin-2 (IL-2) targeted medication (e.g. alemtuzumab, basiliximab) within 60 days prior to study product infusion
  • Treatment with prednisolone at >2 mg/kg/day (or equivalent dosing of alternative glucocorticosteroids) at time of study product infusion.
  • Known allergy/ to any component of the study product
  • Treatment with another drug within one month before inclusion
  • History of neurological impairment (active seizures, severe peripheral neuropathy, signs of leukoencephalopathy, active Central Nervous System (CNS) infection) Note: For patients with heavy pretreatment with irradiation or intrathecal chemotherapy pre-transplant CNS MRI and neurological consultation are mandatory.
  • Fungal infections with radiological and clinical progression
  • Liver function abnormalities with >2 mg/dL and elevation of transaminases higher than 400 U/L
  • Chronic active viral hepatitis
  • \<40% or Shortening fraction \<20% on echocardiography. Patients with > grade II hypertension by Common Toxicity Criteria (CTC)
  • below threshold defined for stem cell transplantation according to local clinical standard
  • Respiratory failure necessitating supplemental oxygen
  • infection
  • Female patients who are pregnant or breast feeding, or adults of not willing to use an effective method of during study treatment and for at least 12 months thereafter Note: Women of must have a negative serum pregnancy test at study entry.
  • Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study
  • Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism/drug addiction)
  • Patients unwilling or unable to comply with the protocol or unable to give
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Single-arm

    Donor lymphocytes from allogeneic donors depleted of CD45RA lymphocytes.

    Biological: CD45RA depleted donor lymphocyte infusion (DLI)

Interventions

  • BiologicalCD45RA depleted donor lymphocyte infusion (DLI)

    CD45RA depleted donor lymphocyte infusion (DLI) after TCRα/β depleted haploidentical HCT

06

What researchers measure

Primary outcomes

  1. Phase I, dose escalation

    Safety and toxicity of CD45RA depleted DLI as defined by infusional toxicities and acute GVHD grad III-IV.

    Time frame: 100 days

  2. Phase II, extension phase

    Acute graft-versus-host disease grade III-IV defined as GVHD occurring within 100 days after HCT

    Time frame: 100 days

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jan 2028, 57 months after the start.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 57 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2023
First posted
Jul 13, 2023
StartActual
Apr 27, 2023
Primary completionEst.
Jan 2028
CompletionEst.
Dec 2028
Last update
Apr 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05943067
Responsible party
Sponsor
First posted
Jul 13, 2023
Start date
Apr 27, 2023
Primary completion
Jan 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Apr 27, 2025

Study contacts

Wolfgang Bethge, MD, PhD
Contact
wolfgang.bethge@med.uni-tuebingen.de
+49 7071 29-83176
Peter Lang, MD, PhD
Contact
peter.lang@med.uni-tuebingen.de
+49 7071 29-81386

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion